HPI-1216

HPI-1216 is an investigational urology product being developed by Hammock Pharmaceuticals as a treatment for radiation cystitis, a painful and potentially debilitating inflammation and bleeding of the bladder that occurs as a common side effect of pelvic radiation therapy for cancers such as prostate, gynecologic, and colorectal malignancies.[5][7] Publicly available information describes HPI-1216 as part of a women’s health and urological technology platform licensed from Milanapharm, but does not disclose its precise active ingredient, molecular modality, or detailed mechanism of action; it is positioned as a localized therapy intended to mitigate bladder injury and improve urinary symptoms in patients receiving or having received pelvic radiotherapy.[5][7]